Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
FP01 - Early Stage/Localized Disease
- Type: Posters (Featured)
- Track: Early Stage/Localized Disease
- Presentations: 5
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP01.03 - Genetic Predisposition for Pre-Invasive Lung Adenocarcinoma Manifesting as Ground-Glass Nodules with Family History of Lung Cancer
00:00 - 00:00 | Presenter: Rui Fu
- Abstract
Loading...
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 4
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP13.04 - KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
FP14 - Targeted Therapy - Clinically Focused
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
- Presentations: 16
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP14.09 - Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
00:00 - 00:00 | Presenter: Rémi Veillon
- Abstract
Loading... -
+
FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.
00:00 - 00:00 | Author(s): giovanni Selvaggi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
FP14.17 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 24
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P01.16 - Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells
00:00 - 00:00 | Presenter: Yun-Ting He
- Abstract
Loading...
-
+
P56 - Tumor Biology and Systems Biology - Basic and Translational Science - CT DNA
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 1
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P56.01 - Postoperative ctDNA Positive Presents the High-risk of Recurrence in Resectable Non-Small Cell Lung Cancers
00:00 - 00:00 | Author(s): Min Zhang
- Abstract
Loading...
-
+
P59 - Tumor Biology and Systems Biology - Basic and Translational Science - Genomics
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 8
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P59.03 - Intratumoral Heterogeneity and Clonal Evolution in Large Non-Small Cell Lung Cancer (>7cm) Delineated by Multiregion Sequencing
00:00 - 00:00 | Presenter: Jia-Tao Zhang
- Abstract
Loading... -
+
P59.04 - Sex-Related Differences in Genomic and Immune Profiling of Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Xue-Tao Li
- Abstract
Loading...
-
+
P72 - Tumor Biology and Systems Biology - Basic and Translational Science - Tumor Microenvironment
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 10
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P72.02 - Cellular Landscape of Tumor Immune Microenvironment and Genetic Signatures Identify Prognostic of LUAD
00:00 - 00:00 | Presenter: Si-Yang Liu
- Abstract
Loading...
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 22
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P75.20 - Outcomes of Lung Cancer Patients with Leptomeningeal Metastases Following Immune Checkpoint Inhibitor Treatments: A Pooled Analysis
00:00 - 00:00 | Presenter: meimei Zheng
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 98
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P76.19 - Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib
00:00 - 00:00 | Presenter: Chang Lu
- Abstract
Loading... -
+
P76.60 - FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
00:00 - 00:00 | Presenter: Adam Pluzanski
- Abstract
Loading... -
+
P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.81 - Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR–RAD51 Fusion: A Brief Report
00:00 - 00:00 | Presenter: Han-Min Wang
- Abstract
Loading... -
+
P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC
00:00 - 00:00 | Presenter: Jianying Zhou
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 16
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P78.03 - Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
00:00 - 00:00 | Presenter: Cheng Huang
- Abstract
Loading...
